Company Overview and News

0
Malaysians don’t mind small homes but make them spacious

2018-06-21 theedgemarkets
IN cities such as Kuala Lumpur where land cost is rising, space comes at a premium, leading to smaller homes being built. Whether one likes it or not, the small homes trend is a given within cities.
8664 3794

11
Newsbreak: Pay cuts for directors of GLCs and government agencies next?

2018-06-18 theedgemarkets
THE government is understood to be mulling over making drastic changes in the appointment and remuneration of directors at government-linked companies (GLCs) and agencies, sources familiar with the matter tell The Edge.
1023 5347 SMEBF TNABY 4197 8664 6874 TNABF CIMDF

156
Battersea Power Station deal above board, say S P Setia, Sime Darby Property

2018-06-13 theedgemarkets
KUALA LUMPUR (June 13): The Battersea Power Station (BPS) is a prime central London development that was acquired by Sime Darby Property Bhd, S P Setia Bhd and the Employees Provident Fund (EPF) through "a competitive tender process" in September 2012, said S P Setia and Sime Darby Property.
AAPL 8664

0
Stocks sink on Battersea probe news

2018-06-13 theedgemarkets
KUALA LUMPUR: Property developers S P Setia Bhd and Sime Darby Property Bhd shares fell yesterday following news that their Battersea Power Station redevelopment project may be investigated as part of “dubious” investments made by the previous government. The declines resulted in their combined market capitalisation of RM1.5 billion wiped out in a single day.
8664

3
FBM KLCI down 11.64 points, ringgit weakens to 3.9940 vs US dollar

2018-06-12 theedgemarkets
KUALA LUMPUR (June 12): The FBM KLCI fell 11.64 points or 0.7% while the ringgit weakened as investors anticipated major central banks' monetary policies this week. At 5pm, the KLCI finished at 1,764.16 points after the ringgit depreciated to its weakest level today against the US dollar at 3.9940.
TGLVY 7113 8664 TPGVF BATS 4162 GEBHF

0
S P Setia, Sime Darby Property fall after Anwar said M'sia to probe Battersea deal

2018-06-12 theedgemarkets
KUALA LUMPUR (June 12): S P Setia Bhd shares slumped as much as 27 sen or 8% to RM2.93 after Datuk Seri Anwar Ibrahim said Malaysia will have to investigate the UK's Battersea Power Station property project in London. Anwar said Malaysia Government-funded deals which are considered dubious will have to be investigated.
8664

15
KLCI down 0.38% as regional markets turn choppy

2018-06-12 theedgemarkets
KUALA LUMPUR (June 12): The FBM KLCI fell 0.38% at the midday break today against the backdrop of choppy regional markets, dragged by select index-linked blue chips.
HLFBF 7251 MLYBY MLYNF UPBMF 1082 7113 5032 8664 TPGVF BATS 4162 2089 9334 2852 TGLVY 1155 0047 5347 3301 TNABY TNABF GEBHF

157
Battersea deals up for review, says Anwar Ibrahim

2018-06-12 theedgemarkets
PETALING JAYA (June 12): The new Pakatan Harapan administration will investigate all the previous government’s dubious investments – including the multi-billion ringgit Battersea Power Station project, said PKR de facto leader Datuk Seri Anwar Ibrahim.
AAPL 8664

0
All we want is to live in a safe environment

2018-06-08 theedgemarkets
IN the recently concluded Lafarge-EdgeProp MYHOME survey, about 59.8% of the nearly 14,000 respondents stated their preference to live within gated communities with amenities.
8664 3794

0
EPF buys Polish retail mall for RM1.4bil

2018-05-21 thestar.com.my
Galeria Katowicka is located in Katowice, about 260km from the Polish capital of Warsaw, and 70km from Krakow, the second-largest city. Katowice metropolitan area has a population of between three and 3.5 million. The EPF in an email said: “This investment is expected to generate an attractive long-term yield for the investors.”
8664

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...